Introduction {#Sec1}
============

Over the past few decades Japan has ranked highly in a number of population health metrics, including the world's longest life expectancy, despite its relatively low per capita healthcare expenditure \[[@CR1]\]. However, the Japanese healthcare system is currently facing significant challenges due to demographic changes and the increasing cost of new technologies in conjunction with modest economic growth, which together have resulted in increasing healthcare expenditure (2005: 7.8% gross domestic product \[GDP\]; 2015: 10.9% GDP) \[[@CR2]\]. In response to a rising demand for healthcare from an aging population and growing public financial constraints, Japan introduced a pilot Health Technology Assessment (HTA) program in 2016 \[[@CR3]\]. While economic evaluation supports healthcare decision-making in many countries \[[@CR4]\], it was relatively unused in Japanese decision-making in the healthcare sector prior to this initiative \[[@CR3]\]. The HTA systematically examines the safety, clinical effectiveness, costs and any legal, ethical or social implications of a drug, medical device or clinical procedure. Cost-effectiveness analyses (CEAs), which frequently form an important part of the HTA, compare the costs of new interventions with their outcomes measured in utility units, most commonly the quality-adjusted life-year (QALY), and capture both quantity- and quality-of-life. CEAs are an important tool to assist healthcare systems in deciding how to allocate resources efficiently between interventions to achieve maximal healthcare gains within a fixed budget \[[@CR5]\].

Diabetes is a major public health concern due to its high prevalence and the associated morbidity, mortality and economic burden of diabetes-related complications \[[@CR6]\]. While the prevalence of diabetes in Japan has remained relatively stable over the past 20 years, except for an increasing trend in elderly age groups \[[@CR2]\], it is expected to increase in Japan from 7.9% in 2010 to 9.8% by 2030 \[[@CR7]\]. Hypoglycemia is a common and serious side effect of many of the agents used to treat type 2 diabetes (T2D), including insulins, sulphonylureas and glinides \[[@CR8]\]. The unpleasant symptoms associated with hypoglycemia can lead to significant anxiety with regard to future events and considerable negative effects on patient quality-of-life, along with significant economic burden through increased healthcare resource utilization \[[@CR9], [@CR10]\]. Hypoglycemia and the fear of hypoglycemia are considered to be limiting factors to optimal glycemic control, affecting both diabetes management and clinical outcomes \[[@CR8]\]. In particular, severe hypoglycemic events are associated with a heightened risk of a range of poor clinical outcomes and complications \[[@CR11]--[@CR13]\].

Insulin degludec (degludec) is a basal insulin with an ultra-long duration of action and stable glucose-lowering profile \[[@CR14]\]. Randomized controlled trials (RCTs) have confirmed that similar improvements in glycemic control can be achieved with fewer hypoglycemic episodes across a broad spectrum of patients with diabetes receiving degludec versus insulin glargine 100 U/mL (glargine U100) \[[@CR15]--[@CR18]\]. From public healthcare payer perspectives over short-term time horizons (1--2 years), degludec has been shown to be cost-effective compared with glargine U100 in patients with type 1 diabetes (T1D) or T2D across a range of global settings \[[@CR19]--[@CR26]\].

The aim of the present analysis was to evaluate the short-term cost-effectiveness of switching Japanese patients with T2D receiving basal--bolus insulin therapy from their previous basal insulin to degludec. This analysis was conducted from a Japanese public healthcare payer perspective and was informed by Japanese real-world data from the Kumamoto Insulin Degludec Observational (KIDUNA) study.

Methods {#Sec2}
=======

The KIDUNA Study {#Sec3}
----------------

The design and primary results of the KIDUNA study have been published previously \[[@CR27]\]. In brief, KIDUNA was a 1-year, prospective, open-label, multicenter, non-randomized, treat-to-target observational study in adult Japanese outpatients with T1D or T2D receiving a basal--bolus insulin regimen. The study included patients with T1D or T2D treated with glargine U100 or insulin detemir (IDet) and a rapid-acting insulin analog who were switched from basal insulin to degludec once-daily (at bedtime) under conditions of routine clinical practice. Any concomitant oral antidiabetic drugs were continued at their pre-switch dose throughout the study.

Body mass index (BMI), glycated hemoglobin (HbA~1c~) and insulin dose were monitored at baseline (just prior to the switch from basal insulin to degludec) and at specified intervals over a 1-year period post-switch. Hypoglycemia rates were compared pre- and post-switch (in the month prior to switching from basal insulin to degludec and in the period 3--6 months after switching, respectively). In KIDUNA, non-severe hypoglycemia was defined as self-reported symptoms of hypoglycemia and/or blood glucose level of \< 70 mg/dL (3.9 mmol/L), and nocturnal events were defined as those occurring between 0001 and 0559 hours (both inclusive). Severe hypoglycemia was defined as hypoglycemia accompanied by severe central nervous system symptoms that could not be resolved by the patient and required assistance.

Model Overview {#Sec4}
--------------

A previously published, open-source model developed in Microsoft Excel \[[@CR26]\] was used to evaluate the short-term cost-effectiveness of switching basal insulin to degludec versus continuing the previous basal insulin in terms of costs (2018 Japanese Yen \[JPY\]) and QALYs, from a Japanese public healthcare payer perspective (Fig. [1](#Fig1){ref-type="fig"} displays the model schematic). The model captured hypoglycemia rates and insulin dosing over a 1-year time horizon, and was informed by the clinical outcomes and baseline characteristics of the T2D cohort (*N* = 135) of the KIDUNA study (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). Baseline data were extrapolated for a hypothetical patient cohort who continued their previous basal insulin regimen (cost of glargine U100 assumed), in order to make the comparison with the degludec simulation arm. Body weight was not captured by the model, as there was no significant difference in BMI after 12 months of treatment with degludec versus at baseline in the KIDUNA T2D cohort (Electronic Supplementary Material \[ESM\] Table S1) \[[@CR27]\].Fig. 1Schematic illustration of the cost-effectiveness model. Basal and bolus insulin doses were modeled as the pre-switch dose for the type 2 diabetes (T2D) Kumamoto Insulin Degludec Observational (KIDUNA) study cohort in both simulation arms. Non-severe hypoglycemia was defined as self-reported symptoms of hypoglycemia and/or a blood glucose level of \< 70 mg/dL (3.9 mmol/L) and defined as nocturnal if occurring between 0001 and 0559 hours (both inclusive), otherwise defined as daytime. ^a^Costs calculated for insulin glargine 100 U/mL (glargine U100); ^b^costs calculated for insulin aspart; ^c^estimated rate ratio (*ERR*) calculated for degludec versus previous basal insulin for the T2D cohort of the KIDUNA study. *HRQoL* Health-related quality-of-life, *ICER* incremental cost-effectiveness ratio, *QALY* quality-adjusted life-year Table 1Baseline characteristics of the type 2 diabetes cohort of the KIDUNA study (*N* = 135) \[[@CR27]\]CharacteristicParameterAge, years63.3 (12.6)Male, *n* (%)74 (54.8)Body mass index, kg/m^2^25.0 (4.0)eGFR, mL/min per 1.73 m^2^66.3 (22.1)HbA~1c~, % (mmol/mol)8.1 (1.4) \[65 (15)\]Duration of diabetes, years15.0 (8.1)Basal insulin, *n* (%) Glargine U100 once-daily57 (42.2) Glargine U100 twice-daily2 (1.5) IDet once-daily71 (52.6) IDet twice-daily5 (3.7)Oral antidiabetic agents, *n* (%) α-Glucosidase inhibitor20 (14.8) Biguanide27 (20.0) Thiazolidinedione7 (5.2) DPP-4 inhibitor47 (34.8)*DPP-4* Dipeptidyl peptidase-4, *eGFR* estimated glomerular filtration rate, *glargine U100* insulin glargine 100 U/mL,*HbA*~*1c*~ glycated hemoglobin, *IDet* insulin detemir,*KIDUNA* Kumamoto Insulin Degludec Observational studyData are presented as the mean with the standard deviation in parenthesis, unless stated otherwise Table 2Input parameters: clinical dataParameterPrevious basal insulinDegludecEffect of treatment switch (to degludec from previous basal insulin)Insulin dose^a^, unitsDose ratio Basal13.813.81 Bolus20.520.51Hypoglycemia rate, episodes per PYERate ratio Daytime non-severe^b^10.405.360.52 Nocturnal non-severe1.510.180.12*PYE* Patient-year of exposureNon-severe hypoglycemia was defined as self-reported symptoms of hypoglycemia and/or blood glucose level of \< 70 mg/dL (3.9 mmol/L) and defined as nocturnal if occurring between 0001 and 0559 hours (both inclusive)^a^Assumes mean body weight of 65 kg^b^Calculated by subtracting the number of nocturnal non-severe episodes from the number of overall non-severe episodes, both reported by the KIDUNA study \[[@CR27]\]

Event Rates and Insulin Doses {#Sec5}
-----------------------------

Treatment differences in clinical outcomes were estimated using rate and dose ratios based on the results from the KIDUNA T2D cohort in the periods before and after the patients were switched to degludec (ESM Table S1). The model only captured treatment effects if there was a statistically significant difference between treatment arms; otherwise the previous basal insulin event rate or dose was assumed for both simulation arms. As the primary analysis of the KIDUNA T2D cohort reported no significant differences in basal or bolus insulin dose requirements following 12 months of treatment with degludec versus the baseline dose of the previous basal insulin \[[@CR27]\], insulin doses were modeled as end-of-study doses in both simulation arms and a mean end-of-study body weight of 65 kg was assumed (derived from the mean baseline BMI value of 25.0 kg/m^2^ reported in the KIDUNA study).

Costs and Utilities {#Sec6}
-------------------

Conservatively, no costs were associated with hypoglycemic events, as (1) there are no Japanese-specific costs for non-severe hypoglycemic events available in the literature, and (2) there were no severe hypoglycemic events recorded for the KIDUNA T2D cohort pre- or post-switch \[[@CR27]\] (ESM Table S1). Health-related quality-of-life utilities were extracted from the literature (Table [3](#Tab3){ref-type="table"}). Assumptions in the base case analysis included a utility associated with the flexible degludec dosing schedule.Table 3Input parameters: costs and utilitiesParameterValueUnitSourceTreatment costs (unit price) Degludec^a^8.34JPYNHI price list Glargine U100^b^6.45JPYNHI price list IAsp^c^6.51JPYNHI price listUtilities Baseline0.8620UtilitySakamaki et al. \[[@CR37]\] Daytime non-severe hypoglycemia− 0.0041DisutilityEvans et al. \[[@CR38]\] Nocturnal non-severe hypoglycemia− 0.0067DisutilityEvans et al. \[[@CR38]\] Flexible dosing0.0060UtilityBoye et al. \[[@CR39]\]*IAsp* Insulin aspart, *JPY* Japanese Yen, *NHI* National Health InsuranceTreatment costs are reported as 2018 list prices based on the NHI drug price list^a^Tresiba® (in FlexTouch® pen) (both Novo Nordisk A/S, Bagsværd, Denmark) JPY 2502 for 300 U^b^Lantus® (in Solostar® pen) (both Sanofi S.A., Paris, France) JPY 1936 for 300 U^c^NovoRapid® (in FlexTouch® pen) (both Novo Nordisk A/S) JPY 1952 for 300 U

Sensitivity Analyses {#Sec7}
--------------------

Deterministic sensitivity analyses were conducted to identify key drivers of outcomes in the base case analysis. These included one-way, exploratory analyses excluding the utility associated with the flexible dosing of degludec, removing treatment differences in daytime or nocturnal non-severe hypoglycemia rates or varying the basal insulin cost in the comparator arm to the cost of biosimilar glargine. Two-way sensitivity analyses were conducted with each of the aforementioned one-way analyses in conjunction with the basal insulin cost of biosimilar glargine in the comparator arm.

Compliance with Ethics Guidelines {#Sec8}
---------------------------------

All participants provided written, informed consent to participate in the KIDUNA study, which was carried out in accordance with the principles stated in the Declaration of Helsinki (amended in 2008 at Seoul). The study protocol was approved by the ethics committee of Kumamoto University (approval number 1580).

Results {#Sec9}
=======

Base Case {#Sec10}
---------

Switching basal insulin to degludec was associated with a mean quality-adjusted life expectancy of 0.8386 QALYs at a mean annual cost of JPY 90,757 per patient, compared with 0.8032 QALYs at a mean annual cost of JPY 81,247 per patient continuing with the previous basal insulin. This yielded an incremental cost-effectiveness ratio (ICER) of JPY 268,811 per QALY gained with degludec versus the previous basal insulin (Table [4](#Tab4){ref-type="table"}).Table 4Results of the base case and sensitivity analysesBase case and sensitivity analysesΔ Annual costs (JPY)^a^Δ QALYs^a^ICER (JPY per QALY)^a^Base case95100.0354268,811 Cost of biosimilar glargine^b^ in previous basal insulin arm17,1540.0354484,906 Excluding flexible dosing utility benefit^c^95100.0294323,715 Excluding daytime hypoglycemia benefit^c^95100.0149637,827 Excluding nocturnal hypoglycemia benefit^c^95100.0265359,299 Cost of biosimilar glargine^b^ in previous basal insulin arm and excluding flexible dosing utility benefit17,1540.0294583,945 Cost of biosimilar glargine^b^ in previous basal insulin arm and excluding daytime hypoglycemia benefit17,1540.01491150,568 Cost of biosimilar glargine^b^ in previous basal insulin arm and excluding nocturnal hypoglycemia benefit17,1540.0265648,135*ICER* incremental cost-effectiveness ratio, *∆* difference,*QALYs* quality-adjusted life-years^a^∆ Annual costs, ∆ QALYs and ICERs are reported for degludec minus previous basal insulin^b^Unit price of JPY 4.91 (biosimilar insulin glargine in MirioPen® \[Eli Lilly and Company, Indianapolis, IN, USA\] JPY 1481 for 300 U)^c^Benefit refers to difference between arms in favor of degludec versus previous basal insulin

Sensitivity Analyses {#Sec11}
--------------------

Switching basal insulin to degludec remained a cost-effective intervention in all sensitivity analyses, which yielded ICERs well below the willingness-to-pay threshold of JPY 5 million per QALY used in the Japanese HTA framework (Table [4](#Tab4){ref-type="table"}). While conclusions on overall cost-effectiveness were insensitive to variations in model assumptions, individual variations in model assumptions did exert a moderate influence on the resulting ICER. The ICER was most sensitive to exclusion of the daytime hypoglycemia benefit with degludec, indicating that this was a key driver of outcomes in the base case. However, assuming the cost of biosimilar glargine in the previous basal insulin simulation arm (keeping efficacy unchanged) did not have a large impact on the resulting ICER. Combined variations in model assumptions exerted a moderate influence on the resulting ICER, most notably exclusion of the daytime hypoglycemia benefit with degludec in conjunction with the cost of biosimilar glargine in the previous basal insulin simulation arm. However, conclusions on overall cost-effectiveness remained unchanged.

Discussion {#Sec12}
==========

Our short-term modeling analysis suggests that, from a Japanese public healthcare payer perspective, switching from patients\' previous basal insulin to degludec would be a cost-effective intervention, with an ICER substantially below the willingness-to-pay threshold of JPY 5 million per QALY used in the Japanese HTA framework \[[@CR28]\]. Sensitivity analyses confirmed the robustness of this finding and also indicated that the daytime non-severe hypoglycemia benefit with degludec was a key driver of outcomes in the base case.

In clinical practice, patients may have the basal insulin component of their diabetes treatment regimen switched for various reasons, including lack of efficacy, unacceptable hypoglycemia rates (which may contribute to patients not achieving glycemic targets), availability, cost and public reimbursement coverage \[[@CR29]\]. Our study adds to a growing body of evidence that degludec is a cost-effective treatment option in various patient populations with diabetes, in this case in patients with T2D receiving basal--bolus insulin therapy who have the basal insulin component of their regimen switched to degludec, from a Japanese public healthcare payer perspective.

This analysis represents the first published CEA of degludec from a Japanese public healthcare payer perspective. Our findings share similarities with the results of several global short-term CEAs of degludec versus glargine U100 from public healthcare payer perspectives, which have also reported that degludec is a cost-effective treatment alternative in patients with T2D receiving basal--bolus therapy, in their respective settings \[[@CR19]--[@CR22], [@CR24], [@CR25]\]. Healthcare in Europe is provided through a wide range of different systems run at individual national levels. The UK has a tax-based healthcare system, whereas healthcare in Japan is provided through a multi-payer social insurance-based system. In Japan, public reimbursement prices for drugs are set as an official price applicable to all healthcare providers and are regularly revised \[[@CR30]\]. In contrast, in the UK, drug list prices often do not reflect the actual cost paid because discounts may be negotiated, for instance through patient access schemes and, consequently, treatment costs may be overestimated if based on list prices.

Most analyses, including the present study, have focused on the short-term effects of insulin dosing and hypoglycemia rates over a 1-year time horizon, and identified hypoglycemia benefits as a large driver of QALY gains with degludec. Pollock et al. reported that severe hypoglycemia was a key driver of QALY gains in their short-term analysis, which also captured cardiovascular outcomes and mortality, in addition to severe hypoglycemia rates and insulin dosing, over a 2-year time horizon \[[@CR19]\]. There are limited data available on the long-term cost effectiveness of degludec versus glargine U100. Most CEAs of insulins are informed by clinical trial data, and the treat-to-target design of clinical trials often results in non-inferior or non-significant differences in glycemic control between treatment arms and, thus, renders long-term modeling based on HbA~1c~ differences non-informative. In their analysis, Pollock et al. performed a sensitivity analysis including additional long-term costs and effects over patient lifetimes that demonstrated similar findings to the main analysis---that, as part of a basal--bolus insulin regimen, degludec was highly cost-effective versus glargine U100 in patients with T2D at high risk of cardiovascular events \[[@CR19]\].

Our analysis has provided a conservative estimate of the cost-effectiveness of switching from basal insulin to degludec, as there were no costs associated with non-severe hypoglycemic events due to the lack of Japanese-specific data available in the literature. Although severe hypoglycemic events requiring hospitalization can pose a significant financial burden on healthcare systems \[[@CR31]\], there are also moderate costs associated with non-severe events relating to an elevated use of consumables, such as self-measured blood glucose tests or additional visits to healthcare professionals, that need to be considered \[[@CR32]\]. Hypoglycemia exerts significant societal costs through lost productivity related to absences from work that were not reflected by our CEA from a public healthcare payer perspective \[[@CR33]\]. Furthermore, fear of hypoglycemia may promote compensatory behaviors in order to avoid future events, such as non-adherence to therapy or decreasing the insulin dose, which can result in poor glycemic control and an increased risk of diabetes-related complications \[[@CR9], [@CR34], [@CR35]\].

To date, most global short-term CEAs of degludec versus glargine U100 have been informed by data from treat-to-target RCTs. The present analysis was based on Japanese real-world evidence (RWE) from the KIDUNA study, in which patients switched basal insulin from either glargine U100 or IDet (assuming the basal insulin cost of glargine U100) to degludec, under conditions of routine clinical practice. RWE can provide insights beyond those addressed by RCTs and are often the sole source of evidence concerning the effects of a medical intervention in community practice, with applications for healthcare decision-making \[[@CR36]\].

This analysis was subject to limitations, including the observational design of the KIDUNA study and the lack of an active comparator arm, both of which present the possibility of confounding. Other limitations to the KIDUNA study include the small study size and self-reporting of hypoglycemia. A general limitation when conducting CEAs of diabetes treatments in Japanese settings is the current paucity of disutility estimates associated with hypoglycemic events for Japanese patients in the literature, which necessitated the application of disutilites reported by comprehensive overseas studies in our analysis. While microvascular and macrovascular complications can have sizeable effects on diabetes-related treatment costs and patient quality-of-life, they were not included in the present analysis. Data on these events were not collected in the KIDUNA study, while the costs and effects associated with these complications may accrue over long timeframes that are outside of the scope of the present short-term modeling analysis.

Key strengths of the present analysis are its simplicity, transparency and homogeneity of model inputs from Japanese sources, which included sourcing clinical outcomes and baseline characteristics to inform the model from the T2D cohort of the KIDUNA study. The base case was highly conservative, only using endpoints from the KIDUNA study with significant differences between treatment arms and assuming no costs associated with non-severe hypoglycemia.

Conclusion {#Sec13}
==========

Based on Japanese RWE, our short-term modeling analysis suggests that switching Japanese patients with T2D receiving a basal--bolus regimen from their previous basal insulin to degludec would be highly cost-effective. These data may help decision-makers in Japan to allocate healthcare resources efficiently.
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